Contents
USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.
Visit United States Adopted Names FAQ to learn more.
Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected].
In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.
The following names for the drugs described are "under consideration" by the USAN Council:
April 2024
Anitocabtagene autoleucel: Antineoplastic; Treatment of multiple myeloma
Berberine ursodeoxycholate: Treatment of non-alcoholic fatty liver disease / non-alcoholic steatohepatitis (NAFLD/NASH), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC)
Beroterkib: Antineoplastic
Eloralintide: Weight loss and glycemic control
Enekinragene inzadenovec: Treatment of osteoarthritis
Enmetazobactam: Antibacterial
Gridegalutamide: Treatment of prostate cancer
Ismidenon: Treatment of neurodegenerative diseases
Istisociclib: Antineoplastic
Labafenogene marselecobac: Treatment of phenylketonuria (PKU)
Mififilcon A: Contact lens material
Navacaprant: Treatment of major depressive disorder
Navacaprant sodium: Treatment of major depressive disorder
Osivelotor: Treatment of sickle cell disease
Pasifolate exatecan: Treatment of tumors that express folic acid receptors
Pirenzepine: Treatment of gastric ulcers and diabetic neuropathy
Progerinin: Treatment of Hutchinson-Gilford Progeria Syndrome (HGPS) and Werner Syndrome (WS)
Psilocybin: Treatment of treatment-resistant depression
Rivunatpagene miziparvovec: Treatment of Wilson disease
Sabirnetug: Treatment of Alzheimer’s disease
Selonabant: Treatment of acute cannabinoid intoxication
Sonrotoclax: Antineoplastic
Tuvimecirnon: Antineoplastic
Tuvimecirnon besylate: Antineoplastic
Tuvusertib: Antineoplastic
Vidutolimod: Antineoplastic
Zongertinib: Antineoplastic
March 2024
Atirmociclib: Antineoplastic
Etalanetug: Treatment of Alzheimer’s disease
Frespaciguat: Treatment of pulmonary hypertension
Imneskibart: Antineoplastic
Imzokitug: Antineoplastic
Lunlekitug: Treatment of cardiovascular and inflammatory diseases
Mevrometostat: Antineoplastic
Midafilcon b: Contact lens material
Naxtarubicin: Antineoplastic
Neldaleucel: Treatment of various hematologic malignancies [such as non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL)] and solid tumors
Nelitolimod: Antineoplastic
Nilotinib laurylsulfate: Treatment of myeloid leukemia
Ocadusertib: Treatment of autoimmune and inflammatory diseases, such as, psoriasis, rheumatoid arthritis (RA) or inflammatory bowel diseases (IBD)
Olomorasib: Antineoplastic
Pebezertinib: Antineoplastic
Ribitol: Treatment of limb-girdle muscular dystrophy type 2I/R9, FKRP-related (LGMD2I/R9)
Rilogrotug: Treatment of cachexia in cancer patients with elevated GDF-15 levels
Ruxoprubart: Treatment of complement mediated diseases
Salanersen: Treatment of spinal muscular atrophy (SMA)
Suzetrigine: Treatment of acute and neuropathic pain
Zelebrudomide: Antineoplastic
February 2024
Bafisontamab: Antineoplastic
Brilaroxazine: Treatment of schizophrenia
Falbikitug: Antineoplastic
Flizasertib: Treatment of inflammatory and autoimmune diseases and disorders
Golcadomide hydrochloride: Antineoplastic
Idrebormilast: Topical treatment of atopic dermatitis and plaque psoriasis
Maplirpacept: Treatment of advanced relapsed or refractory lymphoma or myeloma
Naporafenib: Treatment of cancer
Palazestrant: Treatment of breast cancer
Pritelivir: Treatment and suppression of herpes simplex virus (HSV) infection
Rinvecalinase alfa: Treatment of ischemic related diseases and chronic kidney diseases (CKD)
Risvodetinib: Treatment of Parkinson’s disease
Tarperprumig: Antineoplastic
Temtokibart: Treatment of moderate to severe atopic dermatitis (AD)
Ulviprubart: Treatment of IgA nephropathy in adults
Ulixacaltimide: Reducing the risk of major adverse cardiovascular events in adults
Vonsetamig: Treatment of inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL)